Basal cell adhesion molecule (BCAM) (CD239)

Basal cell adhesion molecule (BCAM), also known as CD239 or the Lutheran blood group glycoprotein, is a transmembrane protein of the immunoglobulin superfamily that functions as a high-affinity receptor for laminin alpha-5, a key component of the extracellular matrix (ECM) (UniProt P50895; Wikipedia). It plays a vital role in mediating cell-matrix and cell-cell adhesion, influencing processes such as cell migration, tissue organization, and signal transduction (NIH; Wikipedia). In normal physiology, CD239 is involved in erythropoiesis, specifically the release of mature red blood cells into circulation (NIH; Eyler & Telen, 2006). Pathologically, CD239 is overexpressed in various epithelial cancers, including ovarian, breast, and lung carcinomas, where it promotes tumor invasion and metastasis by facilitating adhesion to the basement membrane (Kikkawa et al., 2018; NIH). Additionally, it is a critical factor in sickle cell disease, where its upregulation on sickle erythrocytes promotes abnormal adhesion to the vascular endothelium, contributing to vaso-occlusive crises (NIH; Eyler & Telen, 2006). Due to its tumor-specific overexpression and internalization properties, CD239 is being investigated as a target for antibody-drug conjugates (ADCs), such as GENA-111-AF, and other targeted therapies (Debiopharm; Kikkawa et al., 2018).

Other names

BCAMLULutheran antigenLutheran blood group glycoproteinMSK19AUB-CAM cell surface glycoproteinF8/G253 antigenGlycoprotein 95kDaLUAU

The primary mechanism of action for drugs targeting CD239 involves the use of antibody-drug conjugates (ADCs) that bind to the receptor, undergo internalization, and release cytotoxic payloads to kill cancer cells (Kikkawa et al., 2018; Debiopharm). Other approaches include the use of function-blocking antibodies to inhibit the interaction between CD239 and laminin alpha-5, thereby preventing tumor cell migration or reducing vaso-occlusion in sickle cell disease (NIH; Eyler & Telen, 2006).